Clinical Trial Update: Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TC-002 ophthalmic solution to latanoprost for safety and ocular pressure reduction in elevated intraocular pressure; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Elevated Intraocular Pressure
• Glaucoma

Drugs mentioned

• Latanoprost Ophthalmic Solution 0.005% (latanoprost)
• TC-002 Ophthalmic Solution

Snippet

Sponsor: TearClear Corp | Conditions: Elevated Intraocular Pressure | Phase 3 | Status: UNKNOWN